SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has taken a significant step toward becoming a clinical-stage company by initiating a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44, a multi-receptor peptide designed to treat obesity and type 2 diabetes. The program is aligned with U.S. Food and Drug Administration (FDA) requirements and is intended to support an Investigational New Drug (IND) application, a prerequisite for first-in-human clinical trials.
GEP-44 is a next-generation incretin-based therapy developed under a licensing agreement with Syracuse University. Preclinical results position it head-to-head with established treatments such as Ozempic, Mounjaro, and Wegovy. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species. If successful, the data are expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes.
The global GLP-1 receptor agonist market is expanding rapidly, with projections ranging from $100 billion to J.P. Morgan estimates of the broader incretin market reaching $200 billion by 2030. Approximately 25 million patients in the United States alone are expected to use GLP-1 therapies by 2030. SureNano Science, which acquired GlucaPharm to enter this space, is positioning itself as an agile entrant in the next-generation GLP-1 landscape.
In addition to its GLP-1 program, the company is exploring the acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments, signaling a broader pharmaceutical focus. SureNano’s transition toward a pharmaceutical model follows its acquisition of GlucaPharm and reflects its ambition to compete in the high-growth obesity and diabetes market.
The company cautions that forward-looking information involves risks and uncertainties, and actual results may differ materially from expectations. These risks include market prices, study and trial results, continued availability of capital and financing, and general economic conditions. Readers are advised not to place undue reliance on forward-looking statements.
